PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. The PepTivator
®
SARS-CoV-2 Prot_S AY.1 Mutation Pool covers selectively the mutated regions in the surface or spike glycoprotein (“S”) of the SARS-CoV-2 AY.1 lineage (Delta plus variant), a subvariant of B.1.617.2 (Delta variant). PepTivator SARS-CoV-2 Prot_S AY.1 WT Reference Pool consists of the 44 homologous peptides of the Wuhan sequence and serves as a control.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of

Specifications for
PepTivator
®
SARS-CoV-2 Prot_S AY.1

Overview

PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. The PepTivator
®
SARS-CoV-2 Prot_S AY.1 Mutation Pool covers selectively the mutated regions in the surface or spike glycoprotein (“S”) of the SARS-CoV-2 AY.1 lineage (Delta plus variant), a subvariant of B.1.617.2 (Delta variant). PepTivator SARS-CoV-2 Prot_S AY.1 WT Reference Pool consists of the 44 homologous peptides of the Wuhan sequence and serves as a control.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Detailed product information

Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was first detected in December 2019 in Wuhan, China. Since that time the virus kept mutating, leading to new virus variants. The B.1.617.2 lineage, also known as Delta variant, is a SARS-CoV-2 subvariant that was first discovered in India in December 2020. In June 2021, first evidence was reported from Nepal that a B.1.617.2 lineage (Delta variant) with additional mutations appeared. The distinguishing feature of this new subvariant is a K417N substitution in the receptor binding domain of the spike protein. It was assigned to the AY.1 lineage, belongs to VOC Delta G/478K.V1 (B.1.617.2+AY.1+AY.2) and is also called “Delta plus”. The mutations of this variant affect also immune-relevant parts of structural SARS-CoV-2 proteins and the respective sequences are available in GISAID, a genome data base. The mutations listed below are taken from sequence EPI_ISL_2645281. The AY.1 lineage (Delta plus variant) has been found to evade a pre-existing antibody response and appears to be more infectious than other variants.
In total there are 13 mutations in the surface or spike glycoprotein (“S”) of the AY.1 lineage (Delta plus variant) compared to the Wuhan variant (reference genome GenBank MN908947.3): T19R, T95I, G142D, E156G, deletion 157, deletion 158, W258L, K417N, L452R, T478K, D614G, P681R and D950N.
The PepTivator
®
SARS-CoV-2 Prot_S AY.1 Mutation Pool covers selectively the mutated regions. It consists of 44 peptides of 15 aa length. The PepTivator® SARS-CoV-2 Prot_S AY.1 Mutation Pool can be used to supplement PepTivators covering the sequence of the wild-type spike glycoprotein (“S”) in order to detect immune responses towards both variants, Wuhan (wild-type) variant and AY.1 lineage (Delta plus variant). PepTivator Peptide pools spanning the sequence of the spike glycoprotein (“S”) of the Wuhan (wild-type) variant are PepTivator SARS-CoV-2 Prot_S (predicted immunodominant sequence domains), Prot_S1 (N-terminal S1 domain), Prot_S+ (part of the C-terminal S2 domain) and Prot_S Complete (all functional domains).
The PepTivator SARS-CoV-2 Prot_S AY.1 WT Reference Pool consists of the 44 homologous peptides of the Wuhan sequence and covers the positions T19, T95, G142, E156, F157, R158, W258, K417, L452, T478, D614, P681 and D950 of the Wuhan variant (reference genome GenBank MN908947.3).
PepTivator SARS-CoV-2 Prot_S AY.1 WT Reference Pool serves as a control for the SARS-CoV-2 Prot_S AY.1 Mutation Pool. Comparison of the T cell immune response upon stimulation with mutation and reference pool can be used to analyze mutationspecific T cell responses.

Resources for
PepTivator
®
SARS-CoV-2 Prot_S AY.1

References for
PepTivator
®
SARS-CoV-2 Prot_S AY.1

Publications

  1. Ram, R. et al. (2021) Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study Transplant Cell Ther. 27(9): 788-749

Related products for
PepTivator
®
SARS-CoV-2 Prot_S AY.1

9 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?